

PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, SETTINGS)—Continued

PICOTS element	Inclusion criteria	Exclusion criteria
Outcomes	<i>All KQs:</i> Primary efficacy outcomes (<i>i.e.</i> , pain, function, disability, pain interference); harms and adverse effects (<i>e.g.</i> , dizziness, nausea, sedation, development of cannabis use disorder); secondary outcomes (<i>i.e.</i> , psychological distress including depression and anxiety, quality of life, opioid use, sleep quality, sleep disturbance, health care utilization).	<i>All KQs:</i> Other outcomes.
Time of follow-up	<i>All KQs:</i> short term (1 to <6 months), intermediate term (6 to <12 months), long term (≥1 year).	<i>All KQs:</i> studies with <1-month of treatment or followup after treatment.
Setting	<i>All KQs:</i> Any nonhospital setting or setting of self-directed care.	<i>All KQs:</i> Hospital care, hospice care, emergency department care.
Study design	<i>All KQs:</i> RCTs; observational studies with a concurrent control group for harms, and to fill gaps in the evidence for benefits.	<i>All KQs:</i> Other study designs.

Abbreviations: RCT = randomized controlled trial.

Dated: November 27, 2020.

Marquita Cullom,

Associate Director.

[FR Doc. 2020-26570 Filed 12-1-20; 8:45 am]

BILLING CODE 4160-90-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-RFA-PS-21-003, PrEP Choice: Increasing the Use of HIV Pre-exposure Prophylaxis in an Era of Choices; and RFA-PS-21-004, Implementing and Evaluating a Data-to-Care Rx Strategy.

Date: February 23-24, 2021.

Time: 10:00 a.m.–5:00 p.m., EST.

Place: Teleconference, Centers for Disease Control and Prevention, Room

1080, 8 Corporate Square Boulevard, Atlanta, Georgia 30329-4027.

Agenda: To review and evaluate grant applications.

FOR FURTHER INFORMATION CONTACT:

Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329-4027, (404) 718-8833, GAnderson@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2020-26558 Filed 12-1-20; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2020-0121]

Advisory Committee on Immunization Practices (ACIP)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting and request for comment.

SUMMARY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the

following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. The meeting will be webcast live via the World Wide Web.

DATES: The meeting will be held on December 1, 2020 from 2:00 p.m. to 5:00 p.m., EST (times subject to change).

Written comments must be received on or before December 3, 2020.

ADDRESSES: For more information on ACIP please visit the ACIP website: <http://www.cdc.gov/vaccines/acip/index.html>.

You may submit comments, identified by Docket No. CDC-2020-0121 by any of the following methods:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments.
- **Mail:** Docket No. CDC-2020-0121, c/o Attn: November 23, 2020 ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027.

Instructions: All submissions received must include the Agency name and Docket Number. All relevant comments received in conformance with the <https://www.regulations.gov> suitability policy will be posted without change to <https://www.regulations.gov>, including any personal information provided. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee Management Specialist, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, 1600 Clifton Road NE, MS-H24-8, Atlanta, GA 30329-4027; Telephone: 404-639-8367; Email: ACIP@cdc.gov.

SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less than 15 calendar days' notice is